secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001104659-24-059355
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio Q1 revenue $16.6M (+39% YoY); raises FY2024 guidance to $74.5M-$76.5M
------------------------------------------------------------------------------

- Revenue $16.6M, up 39% YoY; 13th consecutive quarter of ≥35% growth.
- OviTex revenue +31% YoY; OviTex PRS +54% YoY.
- Gross margin improved to 68% vs 66% last year; net loss narrowed to $5.7M from $12.0M.
- FY2024 revenue guidance raised to $74.5M-$76.5M (27-31% YoY growth).
- Appointed Howard N. Langstein as VP of Medical Affairs; launched Robotic-Compatible OviTex IHR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465924059355/0001104659-24-059355-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465924059355/tm2411582d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-059355

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer